Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma: a systematic review and meta-analysis.
- Published in:
- Cost Effectiveness & Resource Allocation, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12962-023-00420-4
- By:
- Publication type:
- Article